Weifa ASA

Approved Prospectus and commencement of Subscription Period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES

Oslo, Norway, 26 May 2015

Weifa ASA (OSE: WEIFA), reference is made to the stock exchange announcement by Weifa ASA ("Weifa") on 15 May 2015 and 20 April 2015 regarding the contemplated sale of Weifa's B2B business and tablet production to the newly established company Vistin Pharma AS, and the contemplated equity issue (the "Offering") in Vistin Pharma ASA (the "Company" or "Vistin Pharma").   

The Financial Supervisory Authority of Norway has approved a prospectus prepared by the Company covering the following:

Offering and listing of 15,554,935 New Shares with tradable subscription rights for existing shareholders of Weifa as per the end of 19 May 2015 ("Rights Offering").

Offering and listing of 1,500,000 Employee Offer Shares directed towards the executive management, Board of Directors and employees of the Company ("Employee Offering").

The Offering

The Offering consists of two tranches;

• 15,554,935 new shares at NOK 10.00 per new share (the "New Shares") are directed towards the shareholders of Weifa as of 19 May 2015 (the "Rights Offering"), who are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action (the "Eligible Shareholders"); and
   
• 1,500,000 new shares at NOK 10.00 per new share (the "Employee Offer Shares") are directed towards the Company's full-time employees, executive management and Board of Directors (the "Employee Offering").

The Offering is fully guaranteed primarily by large existing shareholders of Weifa. The underwriters will receive a guarantee commission of 2% of their guaranteed amount, subject to completion of the Offering. Each Underwriter's obligation is subject to approval of the listing of the Company's shares on Oslo Axess by the board of directors of Oslo Børs. For further information regarding the underwriter agreement, please see section 6.1.3 "The Underwriting and the Underwriting Syndicate" in the Prospectus.